-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is converted Medicine original, reproduced please indicate the source Author: Yun Introduction: the internal mechanism of cancer there are many places yet to be discovered, and for cancer patients, these findings have important breakthrough cancer significance.
Scientists funded by the Cancer Institute in the UK have found that for some reason, patients with colorectal cancer have a reduced risk of dying from cancer.
Researchers hope that in the future, doctors can use this information to identify more aggressive bowel cancer patients so that they can receive the most effective treatment.
The research was published in the journal Nature Metabolism, entitled "Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA".
Studies have shown that DNA mutations in the cell energy "factory" increase the survival rate of bowel cancer patients.
Although most of our DNA is wrapped in the center of the cell nucleus, there are also some in the mitochondria.
These mitochondria are tiny structures in cells that help us convert carbon fuels (such as sugar) into energy.
Just as our main nuclear DNA can get errors or "mutations" randomly, so too can the DNA in mitochondria.
It is well known that mitochondrial mutations can be found in cancer cells, but there are few studies on their effects or whether they have an impact on the response to treatment or how the cancer develops.
In order to answer these questions, researchers from the Bison Institute (BI) of the Cancer Research UK and Memorial Sloan Kettering Cancer Center collated and analyzed data from the largest published tumor sample data set, which includes the mitochondrial genome The data and the corresponding clinical results of the patient.
The researchers analyzed data from 344 colorectal cancer patients to match the mutation group with the likelihood of survival.
They found that after controlling for other variables that affect cancer risk, such as age, mitochondrial mutations are associated with a reduced risk of death from colorectal cancer, depending on the type of mitochondrial DNA mutation.
The research team also wants to understand more broadly how common mitochondrial mutations are in cancer.
They used advanced genetic technology to study the existing data of more than 10,000 tumor samples in 23 cancer types to find frequently repeated mitochondrial mutations.
They found that almost 6 out of 10 tumor samples had mitochondrial mutations, and 25 of the 30 most common cancer mutation genes existed in the mitochondrial genome.
These results indicate that mitochondrial mutations may play a role in survival beyond bowel cancer.
This requires further research to understand the broad significance of mitochondrial mutations in different cancers, and in-depth study of the biological basis behind them.
Dr.
Payam Gammage is the co-lead author and team leader of the Beatson Cancer Institute in the United Kingdom.
He said: "This new study reveals the impact of mitochondrial DNA mutations on cancer, which has been overlooked for decades.
This discovery may have implications for patients.
Nursing has a huge impact.
Depending on the mitochondrial DNA status of the cancer, treatment may be changed.
However, further research is needed to transfer these findings from the laboratory to the clinic.
" The researcher said: "Using data hidden in ordinary sight, We have shown that the key part of the cell’s energy production is often destroyed in cancer.
Now, this raises the question of how these mutations in mitochondrial DNA can be used as drug targets.
” Chief Executive Officer of Cancer Research UK Michelle Mitchell said: "This research highlights that there are many areas to be discovered in the internal mechanism of cancer.
For cancer patients, we have not solved all these breakthroughs.
Incredible achievements can be achieved through research .
When we cooperate with world-class global research institutions such as the Sloan-Kettering Cancer Center, we gain even more. We look forward to seeing this unexplored field of research take us far, which may have some amazing potential for cancer patients.
"Reference: [1] https://medicalxpress.
com/news/2021-04-mutations-overlooked-dna-profound-impact.
html [2] -00378-8 Note: This article is intended to introduce the progress of medical research and cannot be used as a reference for treatment plans.
If you need health guidance, please go to a regular hospital.
Scientists funded by the Cancer Institute in the UK have found that for some reason, patients with colorectal cancer have a reduced risk of dying from cancer.
Researchers hope that in the future, doctors can use this information to identify more aggressive bowel cancer patients so that they can receive the most effective treatment.
The research was published in the journal Nature Metabolism, entitled "Respiratory complex and tissue lineage drive recurrent mutations in tumour mtDNA".
Studies have shown that DNA mutations in the cell energy "factory" increase the survival rate of bowel cancer patients.
Although most of our DNA is wrapped in the center of the cell nucleus, there are also some in the mitochondria.
These mitochondria are tiny structures in cells that help us convert carbon fuels (such as sugar) into energy.
Just as our main nuclear DNA can get errors or "mutations" randomly, so too can the DNA in mitochondria.
It is well known that mitochondrial mutations can be found in cancer cells, but there are few studies on their effects or whether they have an impact on the response to treatment or how the cancer develops.
In order to answer these questions, researchers from the Bison Institute (BI) of the Cancer Research UK and Memorial Sloan Kettering Cancer Center collated and analyzed data from the largest published tumor sample data set, which includes the mitochondrial genome The data and the corresponding clinical results of the patient.
The researchers analyzed data from 344 colorectal cancer patients to match the mutation group with the likelihood of survival.
They found that after controlling for other variables that affect cancer risk, such as age, mitochondrial mutations are associated with a reduced risk of death from colorectal cancer, depending on the type of mitochondrial DNA mutation.
The research team also wants to understand more broadly how common mitochondrial mutations are in cancer.
They used advanced genetic technology to study the existing data of more than 10,000 tumor samples in 23 cancer types to find frequently repeated mitochondrial mutations.
They found that almost 6 out of 10 tumor samples had mitochondrial mutations, and 25 of the 30 most common cancer mutation genes existed in the mitochondrial genome.
These results indicate that mitochondrial mutations may play a role in survival beyond bowel cancer.
This requires further research to understand the broad significance of mitochondrial mutations in different cancers, and in-depth study of the biological basis behind them.
Dr.
Payam Gammage is the co-lead author and team leader of the Beatson Cancer Institute in the United Kingdom.
He said: "This new study reveals the impact of mitochondrial DNA mutations on cancer, which has been overlooked for decades.
This discovery may have implications for patients.
Nursing has a huge impact.
Depending on the mitochondrial DNA status of the cancer, treatment may be changed.
However, further research is needed to transfer these findings from the laboratory to the clinic.
" The researcher said: "Using data hidden in ordinary sight, We have shown that the key part of the cell’s energy production is often destroyed in cancer.
Now, this raises the question of how these mutations in mitochondrial DNA can be used as drug targets.
” Chief Executive Officer of Cancer Research UK Michelle Mitchell said: "This research highlights that there are many areas to be discovered in the internal mechanism of cancer.
For cancer patients, we have not solved all these breakthroughs.
Incredible achievements can be achieved through research .
When we cooperate with world-class global research institutions such as the Sloan-Kettering Cancer Center, we gain even more. We look forward to seeing this unexplored field of research take us far, which may have some amazing potential for cancer patients.
"Reference: [1] https://medicalxpress.
com/news/2021-04-mutations-overlooked-dna-profound-impact.
html [2] -00378-8 Note: This article is intended to introduce the progress of medical research and cannot be used as a reference for treatment plans.
If you need health guidance, please go to a regular hospital.
